Cited by 336RNA Research and SplicingDNA Repair MechanismsPARP inhibition in cancer therapy

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

CDK12 regulates DNA repair genes by suppressing intronic polyadenylation

Open access

Dubbury, Sara J., Boutz, Paul L., Sharp, Phillip A.·2018·Nature

DOI 10.1038/s41586-018-0758-yPMC PMC6328294

Open this paper in CoChat — free account Open PDF

Abstract

Mutations that attenuate homologous recombination (HR)-mediated repair promote tumorigenesis and sensitize cells to chemotherapeutics that cause replication fork collapse, a phenotype known as 'BRCAness'1. BRCAness tumours arise from loss-of-function mutations in 22 genes 1. Of these genes, all but one (CDK12) function directly in the HR repair pathway 1. CDK12 phosphorylates serine 2 of the RNA polymerase II C-terminal domain heptapeptide repeat 2-7, a modification that regulates transcription elongation, splicing, and cleavage and polyadenylation 8,9. Genome-wide expression studies suggest that depletion of CDK12 abrogates the expression of several HR genes relatively specifically, thereby blunting HR repair 3-7,10,11. This observation suggests that the mutational status of CDK12 may predict sensitivity to targeted treatments against BRCAness, such as PARP1 inhibitors, and that CDK12 inhibitors may induce sensitization of HR-competent tumours to these treatments 6,7,10,11. Despite growing clinical interest, the mechanism by which CDK12 regulates HR genes remains unknown. Here we show that CDK12 globally suppresses intronic polyadenylation events in mouse embryonic stem cells, enabling the production of full-length gene products. Many HR genes harbour more intronic polyadenylation sites than other expressed genes, and these sites are particularly sensitive to loss of CDK12. The cumulative effect of these sites accounts for the enhanced sensitivity of HR gene expression to CDK12 loss, and we find that this mechanism is conserved in human tumours that contain loss-of-function CDK12 mutations. This work clarifies the function of CDK12 and underscores its potential both as a chemotherapeutic target and as a tumour biomarker.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-018-0758-y

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
Trapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927

Show all 51 references

Sorted by citations

Items 101–200 of 336

Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition
Chang, Y., Wang, X., Yang, J., Tien, J. C.-Y., Mannan, R., Cruz, G., Zhang, Y., Vo, J. N., Magnuson, B., Mahapatra, S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101752 · Cited by 24
Regulation of gene expression by alternative polyadenylation in health and disease
Tian, B., Yu, S., & Zhang, Q. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-025-00928-w · Cited by 23
RNA-biology ruling cancer progression? Focus on 3′UTRs and splicing
Erson-Bensan, A. E. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09884-9 · Cited by 23
Long non-coding RNA generated fromCDKN1Agene by alternative polyadenylation regulates p21 expression during DNA damage response
Murphy, M. R., Ramadei, A., Doymaz, A., Varriano, S., Natelson, D. M., Yu, A., Aktas, S., Mazzeo, M., Mazzeo, M., Zakusilo, G., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad899 · Cited by 24
Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy
Hopkins, J. L., & Zou, L. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.012 · Cited by 25
A combinatorial view of old and new RNA polymerase II modifications
Lyons, D. E., McMahon, S., & Ott, M. (2020) · Transcription · doi:10.1080/21541264.2020.1762468 · Cited by 22
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
Stiegeler, N., Garsed, D. W., Au‐Yeung, G., Bowtell, D. D. L., Heinzelmann-Schwarz, V. A., & Zwimpfer, T. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387281 · Cited by 23
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer
Flippot, R., Patrikidou, A., Aldea, M. D., Colomba, É., Lavaud, P., Albiges, L. K., Naoun, N., Blanchard, P., Terlizzi, M., Garcia, C., et al. (2022) · Drugs · doi:10.1007/s40265-022-01703-5 · Cited by 22
Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment
Masci, D., Naro, C., Puxeddu, M., Urbani, A., Sette, C., Regina, G. L., & Silvestri, R. (2023) · Molecules · doi:10.3390/molecules28227513 · Cited by 25
PAF1C-mediated activation of CDK12/13 kinase activity is critical for CTD phosphorylation and transcript elongation
(2025) · doi:10.1016/j.molcel.2025.04.012 · Cited by 21
CDK12 promotes papillary thyroid cancer progression through regulating the c-myc/β-catenin pathway
Bai, N., Xia, F., Wang, W., Yao, L., Jiang, B., & Li, X. (2020) · Journal of Cancer · doi:10.7150/jca.42849 · Cited by 21
Alternative polyadenylation regulation in cardiac development and cardiovascular disease
Cao, J., & Kuyumcu‐Martinez, M. N. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad014 · Cited by 19
Identifying human pre-mRNA cleavage and polyadenylation factors by genome-wide CRISPR screens using a dual fluorescence readthrough reporter
Ni, Z., Ahmed, N., Nabeel‐Shah, S., Guo, X., Pu, S., Song, J., Marcon, E., Burke, G. L., Tong, A. H. Y., Chan, K., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae240 · Cited by 20
Auto-RapTAC: A Versatile and Sustainable Platform for the Automated Rapid Synthesis and Evaluation of PROTAC
Chen, J., Wu, M., Mo, J., Hong, J.-E., Wang, W., Jin, Y., Mao, X., Liao, X., Li, K., Yu, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02438 · Cited by 19
Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer
Gui, F., Jiang, B., Jiang, J., He, Z., Tsujino, T., Takai, T., Arai, S., Pana, C., Köllermann, J. W., Bradshaw, G. A., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu0847 · Cited by 21
Elements at the 5′ end of Xist harbor SPEN-independent transcriptional antiterminator activity
Trotman, J. B., Lee, D. M., Cherney, R. E., Kim, S. O., Inoue, K., Schertzer, M. D., Bischoff, S. R., Cowley, D. O., & Calabrese, J. M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa789 · Cited by 18
Coming of Age: Targeting Cyclin K in Cancers
Xiao, Y., & Dong, J. (2023) · Cells · doi:10.3390/cells12162044 · Cited by 19
The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation
Schmitz, M., Kaltheuner, I. H., Anand, K., Düster, R., Moecking, J., Monastyrskyi, A., Duckett, D. R., Roush, W. R., & Geyer, M. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105501 · Cited by 20
Cyclin‐dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration‐resistant prostate cancer
Zhang, H., Zhou, Y., Feng, Y., Hou, W., Chen, Y., Xing, Z., Zhang, Y., Wei, Q., Yin, Y., Guo, J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1678 · Cited by 20
Alternative Polyadenylation Is a Novel Strategy for the Regulation of Gene Expression in Response to Stresses in Plants
Wu, J., Ma, L., & Cao, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054727 · Cited by 18
MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma
Pitolli, C., Marini, A., Guerra, M., Pieraccioli, M., Marabitti, V., Palluzzi, F., Giacò, L., Tamburrini, G., Cecconi, F., Nazio, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02790-2 · Cited by 17
Cooperative regulation of coupled oncoprotein synthesis and stability in triple-negative breast cancer by EGFR and CDK12/13
Ang, H. X., Sutiman, N., Deng, X., Liu, A., Cerda-Smith, C. G., Hutchinson, H. M., Kim, H., Bartelt, L. C., Chen, Q., Barrera, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221448120 · Cited by 18
Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
Naro, C., Antonioni, A., Medici, V., Caggiano, C., Jolly, A., de la Grange, P., Bielli, P., Paronetto, M. P., & Sette, C. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02986-0 · Cited by 18
Design, Synthesis, and Biological Evaluation of Novel Orally Available Covalent CDK12/13 Dual Inhibitors for the Treatment of Tumors
Lu, H., Sun, D., Wang, Z., Cui, H., Min, L., Zhang, H., Zhang, Y., Wu, J., Cai, X., Ding, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01616 · Cited by 17
Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation
Yamada, S., Kitai, Y., Tadokoro, T., Takahashi, R., Shoji, H., Maemoto, T., Ishiura, M., Muromoto, R., Kashiwakura, J., Ishii, K. J., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100963 · Cited by 17
CDK13-Mediated Cell Cycle Disorder Promotes Tumorigenesis of High HMGA2 Expression Gastric Cancer
Wu, Z., Wang, M., Li, F., Wang, F., Jia, J., Feng, Z., Huo, X., Yang, J., Wen, J., Sa, R., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.707295 · Cited by 16
Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery
van der Noord, V. E., van de Water, B., & Dévédec, S. E. L. (2022) · Cancers · doi:10.3390/cancers14184353 · Cited by 19
The CDK9-SPT5 Axis in Control of Transcription Elongation by RNAPII
Sun, R., & Fisher, R. P. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168746 · Cited by 16
CRISPRpas: programmable regulation of alternative polyadenylation by dCas9
Shin, J., Ding, Q., Wang, L., Cui, Y., Baljinnyam, E., Güvenek, A., & Tian, B. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab519 · Cited by 19
Discovery of YJZ5118 : A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition
Yang, J., Chang, Y., Zhou, K., Huang, W., Tien, J. C.-Y., Zhang, P., Liu, W., Zhou, L., Zhou, Y., Ren, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00127 · Cited by 15
Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas
Gao, J., Wang, M. Y., Ren, Y., Lwin, T., Li, T., Yan, J. C., Sotomayor, E. M., Duckett, D. R., Shah, B. D., Shain, K. H., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278743 · Cited by 16
Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy
Wu, W., Yu, S., & Yu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188842 · Cited by 16
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer
Yang, Y., Badura, M. L., O’Leary, P. C., Delavan, H. M., Robinson, T. M., Egusa, E. A., Zhong, X., Swinderman, J. T., Li, H., Zhang, M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00848-4 · Cited by 19
Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors
van der Noord, V. E., van der Stel, W., Louwerens, G., Verhoeven, D., Kuiken, H. J., Lieftink, C., Grandits, M., Ecker, G. F., Beijersbergen, R. L., Bouwman, P., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01648-x · Cited by 15
Reciprocal Links between Pre-messenger RNA 3′-End Processing and Genome Stability
Dutertre, M., Sfaxi, R., & Vagner, S. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2021.01.009 · Cited by 17
Control of non-productive RNA polymerase II transcription via its early termination in metazoans
Rouvière, J. O., Lykke‐Andersen, S., & Jensen, T. H. (2022) · Biochemical Society Transactions · doi:10.1042/bst20201140 · Cited by 14
Defining gene ends: RNA polymerase II CTD threonine 4 phosphorylation marks transcription termination regions genome-wide
Kopczyńska, M., Saha, U., Romanenko, A., Nojima, T., Gdula, M. R., & Kamieniarz-Gdula, K. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1240 · Cited by 14
Crosstalk Between mRNA 3'-End Processing and Epigenetics
Soles, L. V., & Shi, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.637705 · Cited by 14
PAF1c links S-phase progression to immune evasion and MYC function in pancreatic carcinoma
Gaballa, A., Gebhardt-Wolf, A., Krenz, B., Mattavelli, G., John, M., Cossa, G., Andreani, S., Schülein‐Völk, C., Montesinos, F., Vidal, R. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45760-8 · Cited by 14
Intronic Polyadenylation in Acquired Cancer Drug Resistance Circumvented by Utilizing CRISPR/Cas9 with Homology-Directed Repair: The Tale of Human DNA Topoisomerase IIα
Elton, T. S., Hernandez, V. A., Carvajal‐Moreno, J., Wang, X., Ipinmoroti, D., & Yalowich, J. C. (2022) · Cancers · doi:10.3390/cancers14133148 · Cited by 15
Targeting DNA repair pathways: mechanisms and potential applications in cancer therapy
Bai, Y., Wang, W., & Wang, J. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00026-7 · Cited by 13
DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic Prostate Cancer
Akhoundova, D., Francica, P., Rottenberg, S., & Rubin, M. A. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000422 · Cited by 13
Comprehensive Analysis of Role of Cyclin-Dependent Kinases Family Members in Colorectal Cancer
Guan, L., Tang, Y., Li, G., Zhao, Q. P., & Li, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.921710 · Cited by 13
ipaQTL-atlas: an atlas of intronic polyadenylation quantitative trait loci across human tissues
Ma, X., Cheng, S., Ding, R., Zhao, Z., Zou, X., Guang, S., Wang, Q., Jing, H., Chen, Y., Ni, T., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac736 · Cited by 14
CDK12 alterations and ARID1A mutations are predictors of poor prognosis and therapeutic targets in high-grade salivary gland carcinoma: analysis of the National Genomic Profiling Database
Kobayashi, K., Saito, Y., Kage, H., Fukuoka, O., Yamamura, K., Mukai, T., Oda, K., & Yamasoba, T. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad066 · Cited by 12
PABPN1, a Target of p63, Modulates Keratinocyte Differentiation through Regulation of p63α mRNA Translation
Mohibi, S., Zhang, J., & Chen, X. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.942 · Cited by 13
Transcriptional CDK Inhibitors as Potential Treatment Option for Testicular Germ Cell Tumors
Funke, K., Düster, R., Wilson, P. D.-G., Arévalo, L., Geyer, M., & Schorle, H. (2022) · Cancers · doi:10.3390/cancers14071690 · Cited by 12
Poly(A) tale: From A to A; RNA polyadenylation in prokaryotes and eukaryotes
Mofayezi, A., Jadaliha, M., Zangeneh, F., & Khoddami, V. (2024) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1837 · Cited by 12
Discovery and design of molecular glue enhancers of CDK12–DDB1 interactions for targeted degradation of cyclin K
Ghosh, P., Schmitz, M., Pandurangan, T., Tadesse, S., Chan, S. C., Mosior, J., Sun, L., Palve, V. C., Grassie, D., Anand, K., et al. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00190g · Cited by 14
Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): Emerging strategies for cancer therapy
Hao, Q., Zhao, W., Li, Z., Lai, Y., Wang, Y., Yang, Q., & Zhang, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117465 · Cited by 12
Structural Mass Spectrometry Probes the Inhibitor-Induced Allosteric Activation of CDK12/CDK13-Cyclin K Dissociation
Bai, Y., Liu, Z., Li, Y., Zhao, H., Lai, C., Zhao, S., Chen, K., Luo, C., Yang, X., & Wang, F. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01697 · Cited by 12
Disrupting the Molecular Pathway in Myotonic Dystrophy
Xing, X., Kumari, A., Brown, J., & Brook, J. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413225 · Cited by 12
Psychological treatment of eating disorders. A review of the literature.
Fassino, S., Pierò, A., Levi, M. P., Gramaglia, C., Amianto, F., Leombruni, P., & Daga, G. A. (2004) · PubMed · Cited by 12
Inhibition of CDK12 elevates cancer cell dependence on P-TEFb by stimulation of RNA polymerase II pause release
Wang, Z., Himanen, S. V., Haikala, H. M., Friedel, C. C., Vihervaara, A., & Barborič, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad792 · Cited by 14
Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12
Troester, S., Eder, T., Wukowits, N., Piontek, M., Fernández‐Pernas, P., Schmoellerl, J., Haladik, B., Manhart, G., Allram, M., Maurer‐Granofszky, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59930-9 · Cited by 15
A patent and literature review of CDK12 inhibitors
Tang, R., Liu, J., Li, S., Zhang, J., Yu, C., Liu, H., Chen, F., Lv, L., Zhang, Q., Yuan, K., et al. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2126765 · Cited by 11
DNA Damage Regulates the Functions of the RNA Binding Protein Sam68 through ATM-Dependent Phosphorylation
Stagni, V., Orecchia, S., Mignini, L., Beji, S., Antonioni, A., Caggiano, C., Barilà, D., Bielli, P., & Sette, C. (2022) · Cancers · doi:10.3390/cancers14163847 · Cited by 12
Aberrant pre-mRNA processing in cancer
Biswas, J., Boussi, L. S., Stein, E. M., & Abdel-Wahab, O. I. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20230891 · Cited by 10
Physiological and pathological roles of the transcriptional kinases CDK12 and CDK13 in the central nervous system
Pitolli, C., Marini, A., Sette, C., & Pagliarini, V. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01413-3 · Cited by 11
New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy
Dai, W., Xie, D., Huang, H., Li, J., Guo, C., Cao, F., Yang, L., Zhong, C., & Liu, S. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101173 · Cited by 12
DNA2 protein destruction dictates DNA hyperexcision, cGAS–STING activation, and innate immune response in CDK12-deregulated cancers
Sun, R., Peng, J. C., Wang, Z., Yan, B., Zhu, S., Huang, Z., Zhang, J., Ding, D., Li, X., Wang, L., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413732122 · Cited by 11
RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target
Pellarin, I., Belletti, B., & Baldassarre, G. (2020) · Medicinal Research Reviews · doi:10.1002/med.21741 · Cited by 10
Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability
Gongora, A. B. L., Marshall, C. H., Velho, P. I., Lopes, C. D. H., Marin, J. F. G., Camargo, A. A., Bastos, D. A., & Antonarakis, E. S. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.11.015 · Cited by 10
Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review
Zheng, S., Chen, Y., Zhu, Z., Li, N., He, C., Koeffler, H. P., Han, X., Wei, Q., & Xu, L. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2500021 · Cited by 9
CDK7–CDK11 axis in spliceosome regulation and pre-mRNA splicing
Rájecký, M., Gajdušková, P., Maník, P., Hluchý, M., Hegedűsová, E., Kryštofová, K., Potěšil, D., Martínková, P., Slabá, Z., Khirsariya, P., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1343 · Cited by 9
Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
Chilà, R., Chiappa, M., Guffanti, F., Panini, N., Conconi, D., Rinaldi, A., Cascione, L., Bertoni, F., Fratelli, M., & Damia, G. L. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903536 · Cited by 9
The PNUTS-PP1 complex acts as an intrinsic barrier to herpesvirus KSHV gene expression and replication
Devlin, A. M., Shukla, A., Ruiz, J. C., Barnes, S. D., Govindan, A., Hunter, O. V., Scarborough, A. M., D’Orso, I., & Conrad, N. K. (2022) · Nature Communications · doi:10.1038/s41467-022-35268-4 · Cited by 9
Regulation of mature mRNA levels by RNA processing efficiency
Henfrey, C., Murphy, S., & Tellier, M. (2022) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqad059 · Cited by 8
DNA damage signals from somatic uterine tissue arrest oogenesis through activated DAF-16
Sarkar, G. C., Rautela, U., Goyala, A., Datta, S., Anand, N., Singh, A., Singh, P., Chamoli, M., & Mukhopadhyay, A. (2023) · Development · doi:10.1242/dev.201472 · Cited by 9
Analysis of CDK12 alterations in a pan‐cancer database
Pan, E., Cabal, A., Javier-DesLoges, J. F., Patel, D. N., Panian, J. A., Lee, S., Shaya, J. A., Nonato, T. K., Xu, X., Stewart, T. F., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4483 · Cited by 10
A review on kinases phosphorylating the carboxyl-terminal domain of RNA polymerase II—Biological functions and inhibitors
Zhang, J., Zhang, X., Huang, H., & Ding, Y. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104318 · Cited by 9
Mechanisms of tandem duplication in the cancer genome
Scully, R., Głodzik, D., Menghi, F., Liu, E. T., & Zhang, C. (2024) · DNA repair · doi:10.1016/j.dnarep.2024.103802 · Cited by 8
Strategies and mechanisms of precision genome engineering: From gene editing to genome writing
Huang, K., Tian, J., Zhao, W., Zhang, S., Xiang, L., Yang, M., Ls, L., Huang, Y., Zhang, N., Sun, L., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70115 · Cited by 8
CDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression
Yanai, Y., Kosaka, T., Nakamura, K., Aimono, E., Matsumoto, K., Morita, S., Mikami, S., Nishihara, H., & Oya, M. (2020) · Cancer Science · doi:10.1111/cas.14672 · Cited by 9
The general transcription factors (GTFs) of RNA polymerase II and their roles in plant development and stress responses
Sharma, S., Kapoor, S., Ansari, A., & Tyagi, A. K. (2024) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2024.2408562 · Cited by 8
A Splice Site Variant of CDK12 and Breast Cancer in Three Eurasian Populations
Bogdanova, N. V., Schürmann, P., Valova, Y. V., Dubrowinskaja, N., Turmanov, N., Yugay, T., Essimsiitova, Z., Mingazheva, E., Prokofyeva, D. S., Bermisheva, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00493 · Cited by 8
Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition
Guo, X., Chen, H., Zhou, Y., Shen, L., Wu, S., & Chen, Y. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2097067 · Cited by 7
Roles of CDK12 mutations in PCa development and treatment
Jiang, C., Hong, Z., Liu, S., Hong, Z., & Dai, B. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189247 · Cited by 8
CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells
Tietz, K. T., McCluskey, B. M., Miller, C. R., Li, Y., Munro, S. A., & Dehm, S. M. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115211 · Cited by 7
Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors
Stern, Y. E., Ghosh, P., Peroza, J., Solanki, H. S., Imbody, D. J., Bridenstine, L., Pandurangan, T., Frydman, S. M., Nickens, K. N., Walker-Mimms, H. L., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0450 · Cited by 7
miR-433 Inhibits Neuronal Growth and Promotes Autophagy in Mouse Hippocampal HT-22 Cell Line
Xu, C., Bai, Q., Wang, C., Meng, Q., Gu, Y., Wang, Q., Xu, W., Han, Y., Qin, Y., Jia, S., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.536913 · Cited by 7
AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells
Zhang, G., Lan, B., Zhang, X., Lin, M., Liu, Y., Chen, J. S., & Guo, F. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006483 · Cited by 7
Comprehensive annotation of 3′UTRs from primary cells and their quantification from scRNA-seq dataPreprint
Fansler, M. M., Mitschka, S., & Mayr, C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.22.469635 · Cited by 7
Alternative polyadenylation: An untapped source for prostate cancer biomarkers and therapeutic targets?
Kurozumi, A., & Lupold, S. E. (2021) · Asian journal of urology · doi:10.1016/j.ajur.2021.05.014 · Cited by 6
Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer
Lautert-Dutra, W., Melo, C. M., Chaves, L. P., Crozier, C., Saggioro, F. P., dos Reis, R. B., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Molecular Cytogenetics · doi:10.1186/s13039-024-00680-6 · Cited by 6
CDK10 suppresses nucleic acid sensors-mediated antitumor immunity
Xu, G., Guo, F., He, C., Wang, X., Xiang, B., Fan, L., Chen, B., Peng, J., Sun, Y., Shi, J., et al. (2026) · Nature Cancer · doi:10.1038/s43018-025-01100-3 · Cited by 5
A Novel Mechanism for Transcription Termination in the mod(mdg4) Locus of Drosophila melanogaster
Soldatova, I. V., Shepelev, M. V., Georgiev, P. G., & Tikhonov, M. V. (2024) · Biology · doi:10.3390/biology13120994 · Cited by 5
Disruption of microhomology-mediated end joining in Ewing sarcoma
Asada, S., Zhu, G., Abeykoon, J. P., Tanaka, Y., Nguyen, H., Hirohashi, Y., Iyer, D., Ashton, N. W., Mukkavalli, S., Velazquez, M., et al. (2026) · Molecular Cell · doi:10.1016/j.molcel.2026.06.038 · Cited by 5
MYC: The Guardian of Its Own Chaos
Gaballa, A., Krenz, B., & Uhl, L. (2025) · BioEssays · doi:10.1002/bies.70010 · Cited by 5
Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis
Al‐Toubat, M., Serrano, S., Elshafei, A., Koul, K., Feibus, A. H., & Balaji, K. C. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2023.09.014 · Cited by 5
Molecular complexity of intraductal carcinoma of the prostate
Zhu, S., Xu, N., & Zeng, H. (2024) · Cancer Medicine · doi:10.1002/cam4.6939 · Cited by 5
Targeting the transcription cycle and RNA processing in cancer treatment
Zhang, L., Zhang, Y., & Hu, X. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.04.001 · Cited by 5
CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma
Liu, Q., Dai, G.-R., Wang, X., Wang, L., Li, L., Wu, Z., & Xia, R.-X. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00415-4 · Cited by 5
Tubular-specific CDK12 knockout causes a defect in urine concentration due to premature cleavage of the slc12a1 gene
Wang, B., Wang, Y., Wen, Y., Zhang, Y., Ni, W., Tang, T., Cao, J.-Y., Yin, Q., Jiang, W., Yin, D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.012 · Cited by 5
Multimodal perturbation analyses of cyclin-dependent kinases reveal a network of synthetic lethalities associated with cell-cycle regulation and transcriptional regulation
Ford, K. M., Munson, B. P., Fong, S. H., Panwala, R., Chu, W. K., Rainaldi, J., Plongthongkum, N., Vinayagam, A., Kostrowicki, J., Meluzzi, D., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33329-2 · Cited by 5
A pan-cancer interrogation of intronic polyadenylation and its association with cancer characteristics
Liu, L., Sun, P., & Zhang, W. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae376 · Cited by 4
Discovery of 4-(2-(methylamino)thiazol-5-yl)pyrimidin-2-amine derivatives as novel cyclin-dependent kinase 12 (CDK12) inhibitors for the treatment of esophageal squamous cell carcinoma
Cao, Y., Huang, S., He, Y., Zhang, Y., Chen, S., Huang, M., He, F., Chen, S., Wang, L., Yang, Z., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108302 · Cited by 4
Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD ?
Schubart, C., Tögel, L., Carta, M. G., Hetzner, P., Helbig, L., Zaglas, C., Ziegler, M., Stöhr, R., Hölsken, A., Hoyer, J., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.35457 · Cited by 4
Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness
Costanzo, F. D., Williamson, J., Robson, C. N., Gaughan, L., Conteduca, V., Mansour, W. Y., Formisano, L., Demichelis, F., Oing, C., & Rescigno, P. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0724 · Cited by 4
CDK12/CDK13 inhibition disrupts transcriptional elongation and replication fork progression in glioblastoma
Lier, S., Markusson, S., Kocijancic, A., Narum, M., Lund, S. O., Böllering, B., Lipsa, A., Soegaard, M. D., Rein, I. D., Sántha, P., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00393-w · Cited by 4

Authors: Dubbury, S. J., Boutz, P. L., & Sharp, P. A.
Affiliations: Koch Institute for Integrative Cancer Research At MIT (US)
University of Rochester Medicine (US)
Corresponding author: Sharp, Phillip A.
ORCID: Dubbury, Sara J.
Boutz, Paul L.
Sharp, Phillip A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2018-11-28
Volume: 564
Issue: 7734
Pages: 141-145
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-018-0758-y
PMC: PMC6328294
OpenAlex: W2806593114
Cited by: 318
References: 51
Citations by year: 2026: 48 · 2025: 35 · 2024: 54 · 2023: 36 · 2022: 46 · 2021: 36 · 2020: 39 · 2019: 23
FWCI: 8.80
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology (P30-CA14051)
National Institutes of Health (GM034277, R01-GM034277)
U.S. Public Health Service (P30-CA14051, R01-GM034277, R01CA133404)
National Cancer Institute (R01CA133404, P01CA042063, CA14051, R01CA226898, P30CA014051, P30-CA-14051)
National Institute of General Medical Sciences (R01GM034277, T32GM007287)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords: CDK12, intronic polyadenylation, homologous recombination, DNA repair genes, BRCAness, PARP-1 inhibitors, CDK12 inhibitors, tumour biomarkers, chemosensitization, mouse embryonic stem cells
MeSH terms: Mouse Embryonic Stem Cells, Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Loss of Function Mutation, Animals, DNA Damage, DNA Repair, Humans, Introns, Mice, Inbred C57BL, Mutation, Neoplasms, Phosphorylation, RNA Polymerase II, Serine, Biomarkers, Tumor, Cyclin-Dependent Kinases, Polyadenylation, Mice, Molecular Targeted Therapy, Homologous Recombination, Transcription Elongation, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CDK12 regulates DNA repair genes by suppressing intronic polyadenylation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks